Alpha Teknova, Inc. (TKNO) – What Are Investment Firms Thinking About This Stock?

Alpha Teknova, Inc. (NASDAQ:TKNO) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $8.75.

Several equities research analysts have recently weighed in on TKNO shares. Wall Street Zen raised shares of Alpha Teknova from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Weiss Ratings lowered Alpha Teknova from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Roth Capital initiated coverage on Alpha Teknova in a report on Wednesday, August 5th. They set a “buy” rating and a $7.00 target price on the stock. TD Cowen boosted their price target on Alpha Teknova from $7.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Zacks Research raised Alpha Teknova to a “hold” rating in a research report on Thursday, August 6th.

Alpha Teknova Stock Down 6.8%

Shares of Alpha Teknova stock opened at $7.08 on Monday. Alpha Teknova has a twelve month low of $1.91 and a twelve month high of $9.48. The stock has a market cap of $379.56 million, a price-to-earnings ratio of -22.84 and a beta of 0.85. The company has a current ratio of 4.49, a quick ratio of 3.48 and a debt-to-equity ratio of 0.21. The company has a fifty day moving average price of $7.74 and a 200 day moving average price of $5.56.

Alpha Teknova (NASDAQ:TKNO) last released its quarterly earnings results on Wednesday, August 5th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.02. The firm had revenue of $12.19 million for the quarter, compared to analyst estimates of $10.95 million. Alpha Teknova had a negative return on equity of 24.94% and a negative net margin of 38.37%. Equities research analysts forecast that Alpha Teknova will post -0.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Alpha Teknova

Institutional investors have recently made changes to their positions in the stock. Susquehanna International Group LLP acquired a new position in Alpha Teknova during the 2nd quarter valued at approximately $115,000. Bank of America Corp DE bought a new position in Alpha Teknova in the 2nd quarter worth about $1,453,000. Ieq Capital LLC acquired a new stake in shares of Alpha Teknova in the second quarter valued at approximately $62,000. BlackRock Inc. acquired a new stake in shares of Alpha Teknova in the second quarter valued at approximately $4,997,000. Finally, Deutsche Bank AG bought a new stake in shares of Alpha Teknova during the second quarter valued at approximately $62,000. 13.81% of the stock is owned by institutional investors.

Alpha Teknova Company Profile

Alpha Teknova, Inc develops and manufactures critical reagents and process solutions used in life sciences research, biopharmaceutical production, cell and gene therapies, vaccines, and molecular diagnostics. The company serves customers that require specialized materials for developing, scaling, and commercializing biological products.

Its product portfolio includes research-grade and current good manufacturing practice (cGMP) buffers, reagents, media, and other process fluids. Alpha Teknova also provides custom formulation, development, manufacturing, and packaging services designed to support applications ranging from laboratory research to regulated commercial production.

Founded in 1996 and headquartered in Hollister, California, Alpha Teknova serves biotechnology, pharmaceutical, diagnostic, academic, and research customers.